-Outlook The structural basis is being laid out for future authoritarianism at the behest of foreign biometric and surveillance technology What distinguishes Barack Obama and David Cameron from Narendra Modi? Obama and Cameron oppose biometric identification but Modi supports it. On 11 May 2005 in the US, the Real ID Act for a national ID was rushed through US Congress and the US Senate with utmost urgency, a legacy of George Bush...

-The Hindu Rajya Sabha returns Aadhaar Bill to Lok Sabha with Opposition amendments . Even as the Opposition aired its concerns over the possibility of mass surveillance, Parliament passed the controversial Aadhaar Bill, 2016, after acrimonious debates in both Houses. In a day marked by high drama, hours after the Opposition succeeded in pushing through five amendments to the Bill in the Rajya Sabha, they were rejected in the Lok Sabha. The amendments...

-The Indian Express There is reason to wonder if this law is intended to be taken seriously, except in getting everyone on the data base, making it a scheme to number the population, and giving extraordinary powers to the UIDAI. The disrespect for the law has been an abiding aspect of the UID project, never mind the government (facts have mattered as little, but that is for another time). In the beginning...

-AP New Delhi: Doctors Without Borders has challenged Pfizer’s application for an Indian patent for its pneumonia vaccine so cheaper versions can be available to children in poor countries and to humanitarian organisations. The medical aid group, also known as Medicins Sans Frontieres, said in a statement late on Friday that it was challenging Pfizer’s patent application to allow Indian manufacturers to make affordable versions of the pneumococcal conjugate vaccine. If Pfizer is...

-The Telegraph New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions. The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not...